Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
New mice, new projects and a newly added area of emphasis have been added to ALS TDI's preclinical drug development repertoire
Posted on Thursday, July 1, 2010 - 15:09, By: Amy Madsen
In continuing efforts to refine its preclinical drug development program, the ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass., has added a new research mouse model to its operations, along with two new projects aimed at helping researchers test and develop therapies in the new mouse.
Posted on Saturday, September 1, 2007 - 09:16, By: Margaret Wahl
Failure to recognize differences among mice with mutated SOD1 genes may be the key to understanding why so many medications that looked good in mouse studies later failed to benefit humans with ALS, say researchers at the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge,...